CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 250 enrolled
Drug / intervention
Amlodipine 5mgdrug
Likely dose
Amlodipine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04692467
NCT04692467Phase 2Completed

Treatment of Early Hypertension Among Persons Living With HIV in Haiti

Weill Medical College of Cornell University·interventional·Posted Dec 31, 2020·Updated Apr 9, 2024

In Brief

A Phase 2 clinical trial evaluating Amlodipine 5mg for HIV/AIDS and Pre Hypertension. Completed, enrolled 250 participants across 1 site.

Detailed Summary

The investigators are conducting an unblinded pilot randomized control trial of 250 persons living with HIV (PLWH), aged 18-65 years, who receive antiretroviral therapy care at Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), are virally suppressed, and have pre-hypertension (systolic blood pressure (SBP) 120-139 or diastolic blood pressure (DBP) 80-89 mmHg) to be randomized to early hypertension (HTN) treatment versus standard of care (SOC). Participants will be recruited from GHESKIO's HIV clinic. Eligible individuals will complete informed consent and be randomized to early HTN treatment vs. SOC. Participants in early HTN treatment will initiate amlodipine immediately versus those in SOC will initiate amlodipine only if they meet the HTN threshold (SBP ≥140 or DBP ≥90 mmHg) during the study period. All participants will be followed for 12 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHaiti

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 31, 2020
Enrollment StartFeb 26, 2021
Primary CompletionJun 30, 2023
Study CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.5 years ago

Interventions

Amlodipine 5mgdrug

Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.